MedTrace Logo

Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective Registry

NCT03368820 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-08-23

No results posted yet for this study

Summary

Therapeutic algorithms for lung cancer are mainly based on randomised controlled trials which excluded patients with severe co-morbidities. Smoking, the main risk factor for lung cancer, is associated with cardiovascular events that may impact on the therapeutic decision.

The aim of this registry is to determine if and how cardiovascular co-morbidities impact on the physicians' decision for anticancer treatment in lung cancer patients by comparing it to the European Lung Cancer Working Party (ELCWP) guidelines

Conditions

  • Lung Neoplasm

Interventions

OTHER

No intervention

Treatment left at the discretion of the participant

Sponsors & Collaborators

  • European Lung Cancer Working Party

    lead OTHER

Principal Investigators

  • Thierry Berghmans, MD, PhD · ELCWP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-04
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03368820 on ClinicalTrials.gov